nodes	percent_of_prediction	percent_of_DWPC	metapath
Zalcitabine—CYP3A7—Progesterone—uterine cancer	0.102	0.169	CbGbCtD
Zalcitabine—CYP3A7-CYP3A51P—Progesterone—uterine cancer	0.102	0.169	CbGbCtD
Zalcitabine—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0778	0.129	CbGbCtD
Zalcitabine—CYP3A5—Progesterone—uterine cancer	0.0768	0.127	CbGbCtD
Zalcitabine—CYP2C9—Progesterone—uterine cancer	0.0515	0.0852	CbGbCtD
Zalcitabine—CYP2D6—Progesterone—uterine cancer	0.0471	0.0779	CbGbCtD
Zalcitabine—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0452	0.0748	CbGbCtD
Zalcitabine—CYP3A5—Etoposide—uterine cancer	0.0344	0.0569	CbGbCtD
Zalcitabine—CYP3A4—Progesterone—uterine cancer	0.03	0.0496	CbGbCtD
Zalcitabine—CYP2D6—Doxorubicin—uterine cancer	0.0144	0.0238	CbGbCtD
Zalcitabine—CYP3A4—Etoposide—uterine cancer	0.0134	0.0222	CbGbCtD
Zalcitabine—CYP3A4—Doxorubicin—uterine cancer	0.00915	0.0151	CbGbCtD
Zalcitabine—Gemcitabine—POLD1—uterine cancer	0.00635	0.481	CrCbGaD
Zalcitabine—Cytarabine—POLD1—uterine cancer	0.00433	0.328	CrCbGaD
Zalcitabine—Gemcitabine—RRM2—uterine cancer	0.00253	0.191	CrCbGaD
Zalcitabine—SLC29A2—female reproductive system—uterine cancer	0.0024	0.0585	CbGeAlD
Zalcitabine—SLC29A2—vagina—uterine cancer	0.00217	0.053	CbGeAlD
Zalcitabine—SLC29A1—myometrium—uterine cancer	0.00204	0.0498	CbGeAlD
Zalcitabine—DCK—myometrium—uterine cancer	0.00195	0.0476	CbGeAlD
Zalcitabine—SLC22A7—renal system—uterine cancer	0.00193	0.047	CbGeAlD
Zalcitabine—SLC29A1—uterine cervix—uterine cancer	0.00159	0.0387	CbGeAlD
Zalcitabine—DCK—uterine cervix—uterine cancer	0.00152	0.037	CbGeAlD
Zalcitabine—SLC29A1—decidua—uterine cancer	0.00151	0.0369	CbGeAlD
Zalcitabine—DCK—Doxorubicin—Epirubicin—uterine cancer	0.00151	0.38	CbGdCrCtD
Zalcitabine—SLC29A1—renal system—uterine cancer	0.00149	0.0362	CbGeAlD
Zalcitabine—DCK—decidua—uterine cancer	0.00145	0.0353	CbGeAlD
Zalcitabine—SLC29A1—endometrium—uterine cancer	0.00144	0.035	CbGeAlD
Zalcitabine—SLC29A2—lymph node—uterine cancer	0.00141	0.0342	CbGeAlD
Zalcitabine—DCK—Epirubicin—Doxorubicin—uterine cancer	0.0014	0.351	CbGdCrCtD
Zalcitabine—SLC29A1—mammalian vulva—uterine cancer	0.00139	0.0339	CbGeAlD
Zalcitabine—DCK—endometrium—uterine cancer	0.00137	0.0335	CbGeAlD
Zalcitabine—DCK—mammalian vulva—uterine cancer	0.00133	0.0324	CbGeAlD
Zalcitabine—SLC29A1—uterus—uterine cancer	0.00133	0.0323	CbGeAlD
Zalcitabine—DCK—uterus—uterine cancer	0.00127	0.0308	CbGeAlD
Zalcitabine—SLC29A1—female reproductive system—uterine cancer	0.00119	0.029	CbGeAlD
Zalcitabine—DCK—female reproductive system—uterine cancer	0.00114	0.0277	CbGeAlD
Zalcitabine—SLC29A1—female gonad—uterine cancer	0.00108	0.0264	CbGeAlD
Zalcitabine—SLC29A1—vagina—uterine cancer	0.00108	0.0263	CbGeAlD
Zalcitabine—DCK—Levonorgestrel—Progesterone—uterine cancer	0.00107	0.269	CbGdCrCtD
Zalcitabine—DCK—female gonad—uterine cancer	0.00104	0.0252	CbGeAlD
Zalcitabine—DCK—vagina—uterine cancer	0.00103	0.0251	CbGeAlD
Zalcitabine—SLC29A1—Fluoropyrimidine Activity—RRM2—uterine cancer	0.000962	0.0579	CbGpPWpGaD
Zalcitabine—CYP3A5—uterine cervix—uterine cancer	0.000787	0.0192	CbGeAlD
Zalcitabine—CYP3A5—renal system—uterine cancer	0.000736	0.0179	CbGeAlD
Zalcitabine—SLC29A1—lymph node—uterine cancer	0.000697	0.017	CbGeAlD
Zalcitabine—DCK—lymph node—uterine cancer	0.000666	0.0162	CbGeAlD
Zalcitabine—CYP2C9—female reproductive system—uterine cancer	0.00058	0.0141	CbGeAlD
Zalcitabine—CYP3A4—renal system—uterine cancer	0.000552	0.0135	CbGeAlD
Zalcitabine—SLC22A7—Fluoropyrimidine Activity—RRM2—uterine cancer	0.000548	0.033	CbGpPWpGaD
Zalcitabine—CYP2D6—renal system—uterine cancer	0.000543	0.0132	CbGeAlD
Zalcitabine—CYP3A5—female gonad—uterine cancer	0.000536	0.0131	CbGeAlD
Zalcitabine—CYP3A5—vagina—uterine cancer	0.000533	0.013	CbGeAlD
Zalcitabine—SLC29A1—Fluoropyrimidine Activity—MTHFR—uterine cancer	0.000487	0.0293	CbGpPWpGaD
Zalcitabine—DCK—Retinoblastoma (RB) in Cancer—MSH6—uterine cancer	0.000453	0.0272	CbGpPWpGaD
Zalcitabine—CYP3A43—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000452	0.0272	CbGpPWpGaD
Zalcitabine—CYP3A43—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000446	0.0268	CbGpPWpGaD
Zalcitabine—CYP3A4—female reproductive system—uterine cancer	0.000442	0.0108	CbGeAlD
Zalcitabine—CYP2D6—female reproductive system—uterine cancer	0.000435	0.0106	CbGeAlD
Zalcitabine—DCK—Nucleotide metabolism—RRM2—uterine cancer	0.000407	0.0245	CbGpPWpGaD
Zalcitabine—CYP2D6—female gonad—uterine cancer	0.000396	0.00965	CbGeAlD
Zalcitabine—DCK—Retinoblastoma (RB) in Cancer—RRM2—uterine cancer	0.000373	0.0224	CbGpPWpGaD
Zalcitabine—CYP3A43—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000367	0.022	CbGpPWpGaD
Zalcitabine—CYP3A43—Metapathway biotransformation—AKR1B10—uterine cancer	0.000345	0.0208	CbGpPWpGaD
Zalcitabine—CYP3A4—Benzo(a)pyrene metabolism—AKR1C1—uterine cancer	0.000342	0.0206	CbGpPWpGaD
Zalcitabine—CYP3A43—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000333	0.02	CbGpPWpGaD
Zalcitabine—CYP3A43—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.000328	0.0197	CbGpPWpGaD
Zalcitabine—CYP3A43—Metapathway biotransformation—AKR1B1—uterine cancer	0.000321	0.0193	CbGpPWpGaD
Zalcitabine—SLC22A7—Fluoropyrimidine Activity—MTHFR—uterine cancer	0.000277	0.0167	CbGpPWpGaD
Zalcitabine—CYP3A43—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.00027	0.0162	CbGpPWpGaD
Zalcitabine—CYP3A4—Benzo(a)pyrene metabolism—AKR1C3—uterine cancer	0.000264	0.0159	CbGpPWpGaD
Zalcitabine—CYP3A43—Metapathway biotransformation—AKR1C1—uterine cancer	0.000236	0.0142	CbGpPWpGaD
Zalcitabine—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000222	0.000692	CcSEcCtD
Zalcitabine—Eye pain—Doxorubicin—uterine cancer	0.000221	0.000691	CcSEcCtD
Zalcitabine—Cardiac failure—Epirubicin—uterine cancer	0.000221	0.000691	CcSEcCtD
Zalcitabine—Hypoglycaemia—Epirubicin—uterine cancer	0.000221	0.000691	CcSEcCtD
Zalcitabine—Hyponatraemia—Epirubicin—uterine cancer	0.000217	0.000677	CcSEcCtD
Zalcitabine—Renal failure acute—Doxorubicin—uterine cancer	0.000217	0.000676	CcSEcCtD
Zalcitabine—Osteoarthritis—Epirubicin—uterine cancer	0.000216	0.000674	CcSEcCtD
Zalcitabine—Gastrointestinal haemorrhage—Epirubicin—uterine cancer	0.000216	0.000674	CcSEcCtD
Zalcitabine—Pain in extremity—Epirubicin—uterine cancer	0.000216	0.000674	CcSEcCtD
Zalcitabine—Feeling abnormal—Dactinomycin—uterine cancer	0.000216	0.000673	CcSEcCtD
Zalcitabine—Ill-defined disorder—Etoposide—uterine cancer	0.000215	0.000672	CcSEcCtD
Zalcitabine—Anaemia—Etoposide—uterine cancer	0.000215	0.000669	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000214	0.000668	CcSEcCtD
Zalcitabine—Hot flush—Doxorubicin—uterine cancer	0.000214	0.000667	CcSEcCtD
Zalcitabine—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000213	0.000666	CcSEcCtD
Zalcitabine—Migraine—Epirubicin—uterine cancer	0.000213	0.000664	CcSEcCtD
Zalcitabine—Affect lability—Epirubicin—uterine cancer	0.000213	0.000664	CcSEcCtD
Zalcitabine—Menopausal symptoms—Doxorubicin—uterine cancer	0.000212	0.000661	CcSEcCtD
Zalcitabine—Dermatitis exfoliative—Doxorubicin—uterine cancer	0.000212	0.000661	CcSEcCtD
Zalcitabine—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000212	0.00066	CcSEcCtD
Zalcitabine—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000211	0.00066	CcSEcCtD
Zalcitabine—Headache—Medroxyprogesterone Acetate—uterine cancer	0.00021	0.000656	CcSEcCtD
Zalcitabine—Renal impairment—Doxorubicin—uterine cancer	0.00021	0.000656	CcSEcCtD
Zalcitabine—Malaise—Etoposide—uterine cancer	0.000209	0.000653	CcSEcCtD
Zalcitabine—Dermatitis bullous—Doxorubicin—uterine cancer	0.000209	0.000653	CcSEcCtD
Zalcitabine—Vertigo—Etoposide—uterine cancer	0.000209	0.000651	CcSEcCtD
Zalcitabine—Leukopenia—Etoposide—uterine cancer	0.000208	0.000648	CcSEcCtD
Zalcitabine—Purpura—Doxorubicin—uterine cancer	0.000207	0.000647	CcSEcCtD
Zalcitabine—Body temperature increased—Dactinomycin—uterine cancer	0.000207	0.000646	CcSEcCtD
Zalcitabine—Abdominal pain—Dactinomycin—uterine cancer	0.000207	0.000646	CcSEcCtD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.000207	0.0124	CbGpPWpGaD
Zalcitabine—CYP3A43—Metapathway biotransformation—GPX3—uterine cancer	0.000207	0.0124	CbGpPWpGaD
Zalcitabine—Cardiac failure—Doxorubicin—uterine cancer	0.000205	0.000639	CcSEcCtD
Zalcitabine—Hypoglycaemia—Doxorubicin—uterine cancer	0.000205	0.000639	CcSEcCtD
Zalcitabine—Mood swings—Epirubicin—uterine cancer	0.000205	0.000639	CcSEcCtD
Zalcitabine—Loss of consciousness—Etoposide—uterine cancer	0.000204	0.000637	CcSEcCtD
Zalcitabine—Ataxia—Epirubicin—uterine cancer	0.000203	0.000634	CcSEcCtD
Zalcitabine—Cough—Etoposide—uterine cancer	0.000203	0.000632	CcSEcCtD
Zalcitabine—Blood creatinine increased—Epirubicin—uterine cancer	0.000202	0.000632	CcSEcCtD
Zalcitabine—Convulsion—Etoposide—uterine cancer	0.000201	0.000628	CcSEcCtD
Zalcitabine—Hyponatraemia—Doxorubicin—uterine cancer	0.000201	0.000626	CcSEcCtD
Zalcitabine—Hypertension—Etoposide—uterine cancer	0.0002	0.000625	CcSEcCtD
Zalcitabine—Osteoarthritis—Doxorubicin—uterine cancer	0.0002	0.000624	CcSEcCtD
Zalcitabine—Pain in extremity—Doxorubicin—uterine cancer	0.0002	0.000624	CcSEcCtD
Zalcitabine—Gastrointestinal haemorrhage—Doxorubicin—uterine cancer	0.0002	0.000624	CcSEcCtD
Zalcitabine—Dry skin—Epirubicin—uterine cancer	0.000198	0.000618	CcSEcCtD
Zalcitabine—Abdominal pain upper—Epirubicin—uterine cancer	0.000197	0.000616	CcSEcCtD
Zalcitabine—Affect lability—Doxorubicin—uterine cancer	0.000197	0.000614	CcSEcCtD
Zalcitabine—Migraine—Doxorubicin—uterine cancer	0.000197	0.000614	CcSEcCtD
Zalcitabine—Hypokalaemia—Epirubicin—uterine cancer	0.000197	0.000614	CcSEcCtD
Zalcitabine—Discomfort—Etoposide—uterine cancer	0.000195	0.000609	CcSEcCtD
Zalcitabine—CYP3A43—Biological oxidations—CYP11A1—uterine cancer	0.000195	0.0117	CbGpPWpGaD
Zalcitabine—Nasopharyngitis—Epirubicin—uterine cancer	0.000193	0.000603	CcSEcCtD
Zalcitabine—Hypersensitivity—Dactinomycin—uterine cancer	0.000193	0.000602	CcSEcCtD
Zalcitabine—CYP3A43—Metapathway biotransformation—CYP11A1—uterine cancer	0.000192	0.0116	CbGpPWpGaD
Zalcitabine—Gastritis—Epirubicin—uterine cancer	0.000191	0.000597	CcSEcCtD
Zalcitabine—Confusional state—Etoposide—uterine cancer	0.000191	0.000596	CcSEcCtD
Zalcitabine—Muscular weakness—Epirubicin—uterine cancer	0.000191	0.000595	CcSEcCtD
Zalcitabine—Mood swings—Doxorubicin—uterine cancer	0.000189	0.000591	CcSEcCtD
Zalcitabine—Infection—Etoposide—uterine cancer	0.000188	0.000587	CcSEcCtD
Zalcitabine—Abdominal distension—Epirubicin—uterine cancer	0.000188	0.000587	CcSEcCtD
Zalcitabine—Ataxia—Doxorubicin—uterine cancer	0.000188	0.000587	CcSEcCtD
Zalcitabine—Asthenia—Dactinomycin—uterine cancer	0.000188	0.000586	CcSEcCtD
Zalcitabine—Blood creatinine increased—Doxorubicin—uterine cancer	0.000187	0.000584	CcSEcCtD
Zalcitabine—Dysphagia—Epirubicin—uterine cancer	0.000187	0.000583	CcSEcCtD
Zalcitabine—Thrombocytopenia—Etoposide—uterine cancer	0.000185	0.000579	CcSEcCtD
Zalcitabine—Tachycardia—Etoposide—uterine cancer	0.000185	0.000577	CcSEcCtD
Zalcitabine—Eosinophilia—Epirubicin—uterine cancer	0.000185	0.000577	CcSEcCtD
Zalcitabine—SLC29A1—Fluoropyrimidine Activity—TP53—uterine cancer	0.000185	0.0111	CbGpPWpGaD
Zalcitabine—Skin disorder—Etoposide—uterine cancer	0.000184	0.000574	CcSEcCtD
Zalcitabine—Dry skin—Doxorubicin—uterine cancer	0.000183	0.000572	CcSEcCtD
Zalcitabine—Hyperhidrosis—Etoposide—uterine cancer	0.000183	0.000571	CcSEcCtD
Zalcitabine—Pancreatitis—Epirubicin—uterine cancer	0.000183	0.000571	CcSEcCtD
Zalcitabine—Abdominal pain upper—Doxorubicin—uterine cancer	0.000183	0.00057	CcSEcCtD
Zalcitabine—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000182	0.011	CbGpPWpGaD
Zalcitabine—Hypokalaemia—Doxorubicin—uterine cancer	0.000182	0.000568	CcSEcCtD
Zalcitabine—CYP3A43—Metapathway biotransformation—AKR1C3—uterine cancer	0.000181	0.0109	CbGpPWpGaD
Zalcitabine—Anorexia—Etoposide—uterine cancer	0.000181	0.000564	CcSEcCtD
Zalcitabine—CYP3A7—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.00018	0.0108	CbGpPWpGaD
Zalcitabine—Diarrhoea—Dactinomycin—uterine cancer	0.000179	0.000559	CcSEcCtD
Zalcitabine—Nasopharyngitis—Doxorubicin—uterine cancer	0.000179	0.000558	CcSEcCtD
Zalcitabine—Gastritis—Doxorubicin—uterine cancer	0.000177	0.000552	CcSEcCtD
Zalcitabine—Muscular weakness—Doxorubicin—uterine cancer	0.000176	0.00055	CcSEcCtD
Zalcitabine—Neutropenia—Epirubicin—uterine cancer	0.000175	0.000545	CcSEcCtD
Zalcitabine—Dysuria—Epirubicin—uterine cancer	0.000175	0.000545	CcSEcCtD
Zalcitabine—Abdominal distension—Doxorubicin—uterine cancer	0.000174	0.000543	CcSEcCtD
Zalcitabine—Dysphagia—Doxorubicin—uterine cancer	0.000173	0.000539	CcSEcCtD
Zalcitabine—Pollakiuria—Epirubicin—uterine cancer	0.000172	0.000538	CcSEcCtD
Zalcitabine—Eosinophilia—Doxorubicin—uterine cancer	0.000171	0.000534	CcSEcCtD
Zalcitabine—Photosensitivity reaction—Epirubicin—uterine cancer	0.00017	0.000532	CcSEcCtD
Zalcitabine—Pancreatitis—Doxorubicin—uterine cancer	0.000169	0.000529	CcSEcCtD
Zalcitabine—Weight decreased—Epirubicin—uterine cancer	0.000169	0.000527	CcSEcCtD
Zalcitabine—Dyspnoea—Etoposide—uterine cancer	0.000169	0.000527	CcSEcCtD
Zalcitabine—Hyperglycaemia—Epirubicin—uterine cancer	0.000168	0.000526	CcSEcCtD
Zalcitabine—Somnolence—Etoposide—uterine cancer	0.000168	0.000526	CcSEcCtD
Zalcitabine—Vomiting—Dactinomycin—uterine cancer	0.000166	0.000519	CcSEcCtD
Zalcitabine—Rash—Dactinomycin—uterine cancer	0.000165	0.000515	CcSEcCtD
Zalcitabine—Decreased appetite—Etoposide—uterine cancer	0.000165	0.000514	CcSEcCtD
Zalcitabine—Fatigue—Etoposide—uterine cancer	0.000163	0.00051	CcSEcCtD
Zalcitabine—Neuropathy peripheral—Epirubicin—uterine cancer	0.000163	0.000509	CcSEcCtD
Zalcitabine—Jaundice—Epirubicin—uterine cancer	0.000162	0.000506	CcSEcCtD
Zalcitabine—Pain—Etoposide—uterine cancer	0.000162	0.000506	CcSEcCtD
Zalcitabine—Dysuria—Doxorubicin—uterine cancer	0.000162	0.000504	CcSEcCtD
Zalcitabine—Neutropenia—Doxorubicin—uterine cancer	0.000162	0.000504	CcSEcCtD
Zalcitabine—Pollakiuria—Doxorubicin—uterine cancer	0.00016	0.000498	CcSEcCtD
Zalcitabine—Photosensitivity reaction—Doxorubicin—uterine cancer	0.000158	0.000492	CcSEcCtD
Zalcitabine—Epistaxis—Epirubicin—uterine cancer	0.000157	0.00049	CcSEcCtD
Zalcitabine—Weight decreased—Doxorubicin—uterine cancer	0.000156	0.000488	CcSEcCtD
Zalcitabine—Sinusitis—Epirubicin—uterine cancer	0.000156	0.000487	CcSEcCtD
Zalcitabine—Feeling abnormal—Etoposide—uterine cancer	0.000156	0.000487	CcSEcCtD
Zalcitabine—Hyperglycaemia—Doxorubicin—uterine cancer	0.000156	0.000486	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Etoposide—uterine cancer	0.000155	0.000483	CcSEcCtD
Zalcitabine—Neuropathy peripheral—Doxorubicin—uterine cancer	0.000151	0.000471	CcSEcCtD
Zalcitabine—Urticaria—Etoposide—uterine cancer	0.00015	0.00047	CcSEcCtD
Zalcitabine—Jaundice—Doxorubicin—uterine cancer	0.00015	0.000469	CcSEcCtD
Zalcitabine—Rhinitis—Epirubicin—uterine cancer	0.00015	0.000468	CcSEcCtD
Zalcitabine—Abdominal pain—Etoposide—uterine cancer	0.00015	0.000467	CcSEcCtD
Zalcitabine—Body temperature increased—Etoposide—uterine cancer	0.00015	0.000467	CcSEcCtD
Zalcitabine—Hepatitis—Epirubicin—uterine cancer	0.000149	0.000466	CcSEcCtD
Zalcitabine—Pharyngitis—Epirubicin—uterine cancer	0.000148	0.000463	CcSEcCtD
Zalcitabine—CYP3A7—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000148	0.00888	CbGpPWpGaD
Zalcitabine—Epistaxis—Doxorubicin—uterine cancer	0.000145	0.000453	CcSEcCtD
Zalcitabine—Sinusitis—Doxorubicin—uterine cancer	0.000145	0.000451	CcSEcCtD
Zalcitabine—Visual impairment—Epirubicin—uterine cancer	0.000144	0.000449	CcSEcCtD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.000143	0.00863	CbGpPWpGaD
Zalcitabine—CYP3A43—Biological oxidations—CYP19A1—uterine cancer	0.000143	0.00862	CbGpPWpGaD
Zalcitabine—CYP3A43—Metapathway biotransformation—CYP19A1—uterine cancer	0.000141	0.0085	CbGpPWpGaD
Zalcitabine—Eye disorder—Epirubicin—uterine cancer	0.00014	0.000436	CcSEcCtD
Zalcitabine—Hypersensitivity—Etoposide—uterine cancer	0.00014	0.000436	CcSEcCtD
Zalcitabine—Tinnitus—Epirubicin—uterine cancer	0.000139	0.000435	CcSEcCtD
Zalcitabine—CYP3A7—Metapathway biotransformation—AKR1B10—uterine cancer	0.000139	0.00836	CbGpPWpGaD
Zalcitabine—Flushing—Epirubicin—uterine cancer	0.000139	0.000433	CcSEcCtD
Zalcitabine—Rhinitis—Doxorubicin—uterine cancer	0.000139	0.000433	CcSEcCtD
Zalcitabine—Hepatitis—Doxorubicin—uterine cancer	0.000138	0.000432	CcSEcCtD
Zalcitabine—Pharyngitis—Doxorubicin—uterine cancer	0.000137	0.000428	CcSEcCtD
Zalcitabine—Asthenia—Etoposide—uterine cancer	0.000136	0.000424	CcSEcCtD
Zalcitabine—Chills—Epirubicin—uterine cancer	0.000134	0.000419	CcSEcCtD
Zalcitabine—Pruritus—Etoposide—uterine cancer	0.000134	0.000418	CcSEcCtD
Zalcitabine—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000134	0.00806	CbGpPWpGaD
Zalcitabine—Arrhythmia—Epirubicin—uterine cancer	0.000134	0.000417	CcSEcCtD
Zalcitabine—Visual impairment—Doxorubicin—uterine cancer	0.000133	0.000416	CcSEcCtD
Zalcitabine—CYP3A7—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.000132	0.00795	CbGpPWpGaD
Zalcitabine—Alopecia—Epirubicin—uterine cancer	0.000132	0.000412	CcSEcCtD
Zalcitabine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000132	0.00792	CbGpPWpGaD
Zalcitabine—CYP3A5—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.00013	0.00781	CbGpPWpGaD
Zalcitabine—Diarrhoea—Etoposide—uterine cancer	0.00013	0.000404	CcSEcCtD
Zalcitabine—CYP3A7—Metapathway biotransformation—AKR1B1—uterine cancer	0.000129	0.00778	CbGpPWpGaD
Zalcitabine—Eye disorder—Doxorubicin—uterine cancer	0.000129	0.000403	CcSEcCtD
Zalcitabine—Tinnitus—Doxorubicin—uterine cancer	0.000129	0.000402	CcSEcCtD
Zalcitabine—Flushing—Doxorubicin—uterine cancer	0.000128	0.000401	CcSEcCtD
Zalcitabine—Flatulence—Epirubicin—uterine cancer	0.000128	0.0004	CcSEcCtD
Zalcitabine—Tension—Epirubicin—uterine cancer	0.000128	0.000398	CcSEcCtD
Zalcitabine—Dysgeusia—Epirubicin—uterine cancer	0.000127	0.000398	CcSEcCtD
Zalcitabine—Nervousness—Epirubicin—uterine cancer	0.000126	0.000394	CcSEcCtD
Zalcitabine—Back pain—Epirubicin—uterine cancer	0.000126	0.000393	CcSEcCtD
Zalcitabine—Dizziness—Etoposide—uterine cancer	0.000125	0.000391	CcSEcCtD
Zalcitabine—Muscle spasms—Epirubicin—uterine cancer	0.000125	0.00039	CcSEcCtD
Zalcitabine—Chills—Doxorubicin—uterine cancer	0.000124	0.000387	CcSEcCtD
Zalcitabine—Arrhythmia—Doxorubicin—uterine cancer	0.000124	0.000386	CcSEcCtD
Zalcitabine—Vision blurred—Epirubicin—uterine cancer	0.000123	0.000383	CcSEcCtD
Zalcitabine—Alopecia—Doxorubicin—uterine cancer	0.000122	0.000381	CcSEcCtD
Zalcitabine—Ill-defined disorder—Epirubicin—uterine cancer	0.000121	0.000377	CcSEcCtD
Zalcitabine—Vomiting—Etoposide—uterine cancer	0.00012	0.000376	CcSEcCtD
Zalcitabine—Anaemia—Epirubicin—uterine cancer	0.00012	0.000375	CcSEcCtD
Zalcitabine—Agitation—Epirubicin—uterine cancer	0.00012	0.000373	CcSEcCtD
Zalcitabine—Rash—Etoposide—uterine cancer	0.000119	0.000373	CcSEcCtD
Zalcitabine—Dermatitis—Etoposide—uterine cancer	0.000119	0.000372	CcSEcCtD
Zalcitabine—Headache—Etoposide—uterine cancer	0.000119	0.00037	CcSEcCtD
Zalcitabine—Flatulence—Doxorubicin—uterine cancer	0.000119	0.00037	CcSEcCtD
Zalcitabine—Tension—Doxorubicin—uterine cancer	0.000118	0.000369	CcSEcCtD
Zalcitabine—Dysgeusia—Doxorubicin—uterine cancer	0.000118	0.000368	CcSEcCtD
Zalcitabine—Malaise—Epirubicin—uterine cancer	0.000117	0.000366	CcSEcCtD
Zalcitabine—Nervousness—Doxorubicin—uterine cancer	0.000117	0.000365	CcSEcCtD
Zalcitabine—Vertigo—Epirubicin—uterine cancer	0.000117	0.000365	CcSEcCtD
Zalcitabine—Syncope—Epirubicin—uterine cancer	0.000117	0.000364	CcSEcCtD
Zalcitabine—Leukopenia—Epirubicin—uterine cancer	0.000116	0.000363	CcSEcCtD
Zalcitabine—Back pain—Doxorubicin—uterine cancer	0.000116	0.000363	CcSEcCtD
Zalcitabine—Muscle spasms—Doxorubicin—uterine cancer	0.000116	0.000361	CcSEcCtD
Zalcitabine—Palpitations—Epirubicin—uterine cancer	0.000115	0.000359	CcSEcCtD
Zalcitabine—Loss of consciousness—Epirubicin—uterine cancer	0.000114	0.000357	CcSEcCtD
Zalcitabine—DCK—Retinoblastoma (RB) in Cancer—CDKN1B—uterine cancer	0.000114	0.00685	CbGpPWpGaD
Zalcitabine—Cough—Epirubicin—uterine cancer	0.000114	0.000354	CcSEcCtD
Zalcitabine—Vision blurred—Doxorubicin—uterine cancer	0.000113	0.000354	CcSEcCtD
Zalcitabine—Convulsion—Epirubicin—uterine cancer	0.000113	0.000352	CcSEcCtD
Zalcitabine—Hypertension—Epirubicin—uterine cancer	0.000112	0.000351	CcSEcCtD
Zalcitabine—Ill-defined disorder—Doxorubicin—uterine cancer	0.000112	0.000349	CcSEcCtD
Zalcitabine—Anaemia—Doxorubicin—uterine cancer	0.000111	0.000347	CcSEcCtD
Zalcitabine—Myalgia—Epirubicin—uterine cancer	0.000111	0.000346	CcSEcCtD
Zalcitabine—Arthralgia—Epirubicin—uterine cancer	0.000111	0.000346	CcSEcCtD
Zalcitabine—Agitation—Doxorubicin—uterine cancer	0.000111	0.000345	CcSEcCtD
Zalcitabine—Anxiety—Epirubicin—uterine cancer	0.00011	0.000344	CcSEcCtD
Zalcitabine—Discomfort—Epirubicin—uterine cancer	0.000109	0.000342	CcSEcCtD
Zalcitabine—CYP3A7—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000109	0.00653	CbGpPWpGaD
Zalcitabine—Malaise—Doxorubicin—uterine cancer	0.000109	0.000339	CcSEcCtD
Zalcitabine—Dry mouth—Epirubicin—uterine cancer	0.000108	0.000338	CcSEcCtD
Zalcitabine—Vertigo—Doxorubicin—uterine cancer	0.000108	0.000338	CcSEcCtD
Zalcitabine—Syncope—Doxorubicin—uterine cancer	0.000108	0.000337	CcSEcCtD
Zalcitabine—Leukopenia—Doxorubicin—uterine cancer	0.000108	0.000336	CcSEcCtD
Zalcitabine—Confusional state—Epirubicin—uterine cancer	0.000107	0.000334	CcSEcCtD
Zalcitabine—CYP3A5—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000107	0.00642	CbGpPWpGaD
Zalcitabine—Palpitations—Doxorubicin—uterine cancer	0.000106	0.000332	CcSEcCtD
Zalcitabine—Oedema—Epirubicin—uterine cancer	0.000106	0.000331	CcSEcCtD
Zalcitabine—Loss of consciousness—Doxorubicin—uterine cancer	0.000106	0.00033	CcSEcCtD
Zalcitabine—Infection—Epirubicin—uterine cancer	0.000105	0.000329	CcSEcCtD
Zalcitabine—SLC22A7—Fluoropyrimidine Activity—TP53—uterine cancer	0.000105	0.00633	CbGpPWpGaD
Zalcitabine—Cough—Doxorubicin—uterine cancer	0.000105	0.000328	CcSEcCtD
Zalcitabine—Shock—Epirubicin—uterine cancer	0.000104	0.000326	CcSEcCtD
Zalcitabine—Convulsion—Doxorubicin—uterine cancer	0.000104	0.000326	CcSEcCtD
Zalcitabine—Thrombocytopenia—Epirubicin—uterine cancer	0.000104	0.000324	CcSEcCtD
Zalcitabine—Hypertension—Doxorubicin—uterine cancer	0.000104	0.000324	CcSEcCtD
Zalcitabine—Tachycardia—Epirubicin—uterine cancer	0.000104	0.000323	CcSEcCtD
Zalcitabine—Skin disorder—Epirubicin—uterine cancer	0.000103	0.000322	CcSEcCtD
Zalcitabine—Hyperhidrosis—Epirubicin—uterine cancer	0.000103	0.00032	CcSEcCtD
Zalcitabine—Myalgia—Doxorubicin—uterine cancer	0.000102	0.00032	CcSEcCtD
Zalcitabine—Arthralgia—Doxorubicin—uterine cancer	0.000102	0.00032	CcSEcCtD
Zalcitabine—Anxiety—Doxorubicin—uterine cancer	0.000102	0.000319	CcSEcCtD
Zalcitabine—CYP2C9—Arachidonic acid metabolism—AKR1C3—uterine cancer	0.000101	0.0061	CbGpPWpGaD
Zalcitabine—Discomfort—Doxorubicin—uterine cancer	0.000101	0.000316	CcSEcCtD
Zalcitabine—Anorexia—Epirubicin—uterine cancer	0.000101	0.000316	CcSEcCtD
Zalcitabine—CYP3A5—Metapathway biotransformation—AKR1B10—uterine cancer	0.000101	0.00605	CbGpPWpGaD
Zalcitabine—Dry mouth—Doxorubicin—uterine cancer	0.0001	0.000313	CcSEcCtD
Zalcitabine—Confusional state—Doxorubicin—uterine cancer	9.91e-05	0.000309	CcSEcCtD
Zalcitabine—Oedema—Doxorubicin—uterine cancer	9.82e-05	0.000307	CcSEcCtD
Zalcitabine—Infection—Doxorubicin—uterine cancer	9.76e-05	0.000305	CcSEcCtD
Zalcitabine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	9.68e-05	0.00583	CbGpPWpGaD
Zalcitabine—Musculoskeletal discomfort—Epirubicin—uterine cancer	9.67e-05	0.000302	CcSEcCtD
Zalcitabine—Shock—Doxorubicin—uterine cancer	9.67e-05	0.000302	CcSEcCtD
Zalcitabine—Thrombocytopenia—Doxorubicin—uterine cancer	9.62e-05	0.0003	CcSEcCtD
Zalcitabine—Insomnia—Epirubicin—uterine cancer	9.6e-05	0.0003	CcSEcCtD
Zalcitabine—Tachycardia—Doxorubicin—uterine cancer	9.59e-05	0.000299	CcSEcCtD
Zalcitabine—CYP3A5—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	9.56e-05	0.00575	CbGpPWpGaD
Zalcitabine—Skin disorder—Doxorubicin—uterine cancer	9.54e-05	0.000298	CcSEcCtD
Zalcitabine—Hyperhidrosis—Doxorubicin—uterine cancer	9.5e-05	0.000296	CcSEcCtD
Zalcitabine—CYP3A7—Metapathway biotransformation—AKR1C1—uterine cancer	9.49e-05	0.00571	CbGpPWpGaD
Zalcitabine—Dyspnoea—Epirubicin—uterine cancer	9.47e-05	0.000295	CcSEcCtD
Zalcitabine—Somnolence—Epirubicin—uterine cancer	9.44e-05	0.000295	CcSEcCtD
Zalcitabine—Anorexia—Doxorubicin—uterine cancer	9.37e-05	0.000292	CcSEcCtD
Zalcitabine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	9.36e-05	0.00563	CbGpPWpGaD
Zalcitabine—Dyspepsia—Epirubicin—uterine cancer	9.35e-05	0.000292	CcSEcCtD
Zalcitabine—CYP3A5—Metapathway biotransformation—AKR1B1—uterine cancer	9.34e-05	0.00562	CbGpPWpGaD
Zalcitabine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	9.28e-05	0.00558	CbGpPWpGaD
Zalcitabine—CYP2D6—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	9.24e-05	0.00556	CbGpPWpGaD
Zalcitabine—Decreased appetite—Epirubicin—uterine cancer	9.23e-05	0.000288	CcSEcCtD
Zalcitabine—CYP2C9—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	9.16e-05	0.00551	CbGpPWpGaD
Zalcitabine—Fatigue—Epirubicin—uterine cancer	9.15e-05	0.000286	CcSEcCtD
Zalcitabine—Pain—Epirubicin—uterine cancer	9.08e-05	0.000283	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Doxorubicin—uterine cancer	8.95e-05	0.000279	CcSEcCtD
Zalcitabine—Insomnia—Doxorubicin—uterine cancer	8.89e-05	0.000277	CcSEcCtD
Zalcitabine—Dyspnoea—Doxorubicin—uterine cancer	8.76e-05	0.000273	CcSEcCtD
Zalcitabine—Feeling abnormal—Epirubicin—uterine cancer	8.75e-05	0.000273	CcSEcCtD
Zalcitabine—Somnolence—Doxorubicin—uterine cancer	8.73e-05	0.000273	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Epirubicin—uterine cancer	8.68e-05	0.000271	CcSEcCtD
Zalcitabine—Dyspepsia—Doxorubicin—uterine cancer	8.65e-05	0.00027	CcSEcCtD
Zalcitabine—Decreased appetite—Doxorubicin—uterine cancer	8.54e-05	0.000267	CcSEcCtD
Zalcitabine—Fatigue—Doxorubicin—uterine cancer	8.47e-05	0.000264	CcSEcCtD
Zalcitabine—Urticaria—Epirubicin—uterine cancer	8.44e-05	0.000263	CcSEcCtD
Zalcitabine—Pain—Doxorubicin—uterine cancer	8.4e-05	0.000262	CcSEcCtD
Zalcitabine—Abdominal pain—Epirubicin—uterine cancer	8.39e-05	0.000262	CcSEcCtD
Zalcitabine—Body temperature increased—Epirubicin—uterine cancer	8.39e-05	0.000262	CcSEcCtD
Zalcitabine—CYP3A7—Metapathway biotransformation—GPX3—uterine cancer	8.33e-05	0.00501	CbGpPWpGaD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—ABCC9—uterine cancer	8.17e-05	0.00491	CbGpPWpGaD
Zalcitabine—Feeling abnormal—Doxorubicin—uterine cancer	8.1e-05	0.000253	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Doxorubicin—uterine cancer	8.03e-05	0.000251	CcSEcCtD
Zalcitabine—CYP3A5—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	7.85e-05	0.00472	CbGpPWpGaD
Zalcitabine—CYP3A7—Biological oxidations—CYP11A1—uterine cancer	7.84e-05	0.00472	CbGpPWpGaD
Zalcitabine—Hypersensitivity—Epirubicin—uterine cancer	7.82e-05	0.000244	CcSEcCtD
Zalcitabine—DCK—Metabolism—SRD5A2—uterine cancer	7.82e-05	0.0047	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—NDUFB11—uterine cancer	7.82e-05	0.0047	CbGpPWpGaD
Zalcitabine—Urticaria—Doxorubicin—uterine cancer	7.8e-05	0.000244	CcSEcCtD
Zalcitabine—Body temperature increased—Doxorubicin—uterine cancer	7.77e-05	0.000242	CcSEcCtD
Zalcitabine—Abdominal pain—Doxorubicin—uterine cancer	7.77e-05	0.000242	CcSEcCtD
Zalcitabine—CYP3A7—Metapathway biotransformation—CYP11A1—uterine cancer	7.73e-05	0.00465	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—NDUFB11—uterine cancer	7.7e-05	0.00463	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—SRD5A2—uterine cancer	7.7e-05	0.00463	CbGpPWpGaD
Zalcitabine—Asthenia—Epirubicin—uterine cancer	7.62e-05	0.000238	CcSEcCtD
Zalcitabine—CYP2D6—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	7.59e-05	0.00456	CbGpPWpGaD
Zalcitabine—CYP2C9—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	7.52e-05	0.00453	CbGpPWpGaD
Zalcitabine—Pruritus—Epirubicin—uterine cancer	7.51e-05	0.000234	CcSEcCtD
Zalcitabine—CYP3A7—Metapathway biotransformation—AKR1C3—uterine cancer	7.3e-05	0.00439	CbGpPWpGaD
Zalcitabine—Diarrhoea—Epirubicin—uterine cancer	7.27e-05	0.000227	CcSEcCtD
Zalcitabine—Hypersensitivity—Doxorubicin—uterine cancer	7.24e-05	0.000226	CcSEcCtD
Zalcitabine—DCK—Retinoblastoma (RB) in Cancer—TP53—uterine cancer	7.16e-05	0.00431	CbGpPWpGaD
Zalcitabine—CYP2D6—Metapathway biotransformation—AKR1B10—uterine cancer	7.15e-05	0.0043	CbGpPWpGaD
Zalcitabine—CYP2C9—Metapathway biotransformation—AKR1B10—uterine cancer	7.08e-05	0.00426	CbGpPWpGaD
Zalcitabine—Asthenia—Doxorubicin—uterine cancer	7.05e-05	0.00022	CcSEcCtD
Zalcitabine—Dizziness—Epirubicin—uterine cancer	7.02e-05	0.000219	CcSEcCtD
Zalcitabine—Pruritus—Doxorubicin—uterine cancer	6.95e-05	0.000217	CcSEcCtD
Zalcitabine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	6.89e-05	0.00414	CbGpPWpGaD
Zalcitabine—CYP3A5—Metapathway biotransformation—AKR1C1—uterine cancer	6.86e-05	0.00413	CbGpPWpGaD
Zalcitabine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	6.83e-05	0.00411	CbGpPWpGaD
Zalcitabine—CYP2D6—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	6.8e-05	0.00409	CbGpPWpGaD
Zalcitabine—Vomiting—Epirubicin—uterine cancer	6.75e-05	0.000211	CcSEcCtD
Zalcitabine—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	6.74e-05	0.00405	CbGpPWpGaD
Zalcitabine—Diarrhoea—Doxorubicin—uterine cancer	6.72e-05	0.00021	CcSEcCtD
Zalcitabine—Rash—Epirubicin—uterine cancer	6.69e-05	0.000209	CcSEcCtD
Zalcitabine—Dermatitis—Epirubicin—uterine cancer	6.69e-05	0.000209	CcSEcCtD
Zalcitabine—Headache—Epirubicin—uterine cancer	6.65e-05	0.000208	CcSEcCtD
Zalcitabine—CYP2D6—Metapathway biotransformation—AKR1B1—uterine cancer	6.64e-05	0.004	CbGpPWpGaD
Zalcitabine—CYP2C9—Metapathway biotransformation—AKR1B1—uterine cancer	6.59e-05	0.00396	CbGpPWpGaD
Zalcitabine—Dizziness—Doxorubicin—uterine cancer	6.5e-05	0.000203	CcSEcCtD
Zalcitabine—Vomiting—Doxorubicin—uterine cancer	6.25e-05	0.000195	CcSEcCtD
Zalcitabine—Rash—Doxorubicin—uterine cancer	6.19e-05	0.000193	CcSEcCtD
Zalcitabine—Dermatitis—Doxorubicin—uterine cancer	6.19e-05	0.000193	CcSEcCtD
Zalcitabine—Headache—Doxorubicin—uterine cancer	6.15e-05	0.000192	CcSEcCtD
Zalcitabine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	6.12e-05	0.00368	CbGpPWpGaD
Zalcitabine—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	6.04e-05	0.00363	CbGpPWpGaD
Zalcitabine—CYP3A5—Metapathway biotransformation—GPX3—uterine cancer	6.02e-05	0.00362	CbGpPWpGaD
Zalcitabine—CYP3A7—Biological oxidations—CYP19A1—uterine cancer	5.77e-05	0.00347	CbGpPWpGaD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—ABCC9—uterine cancer	5.73e-05	0.00345	CbGpPWpGaD
Zalcitabine—CYP3A7—Metapathway biotransformation—CYP19A1—uterine cancer	5.69e-05	0.00342	CbGpPWpGaD
Zalcitabine—CYP3A5—Biological oxidations—CYP11A1—uterine cancer	5.67e-05	0.00341	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—AKR1B1—uterine cancer	5.65e-05	0.0034	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—STAR—uterine cancer	5.65e-05	0.0034	CbGpPWpGaD
Zalcitabine—CYP3A5—Metapathway biotransformation—CYP11A1—uterine cancer	5.59e-05	0.00336	CbGpPWpGaD
Zalcitabine—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	5.58e-05	0.00336	CbGpPWpGaD
Zalcitabine—CYP3A4—Tryptophan metabolism—CYP19A1—uterine cancer	5.57e-05	0.00335	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—STAR—uterine cancer	5.56e-05	0.00335	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—AKR1B1—uterine cancer	5.56e-05	0.00335	CbGpPWpGaD
Zalcitabine—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	5.53e-05	0.00333	CbGpPWpGaD
Zalcitabine—CYP3A5—Metapathway biotransformation—AKR1C3—uterine cancer	5.28e-05	0.00318	CbGpPWpGaD
Zalcitabine—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	4.96e-05	0.00298	CbGpPWpGaD
Zalcitabine—CYP2D6—Metapathway biotransformation—AKR1C1—uterine cancer	4.88e-05	0.00293	CbGpPWpGaD
Zalcitabine—CYP2C9—Metapathway biotransformation—AKR1C1—uterine cancer	4.83e-05	0.00291	CbGpPWpGaD
Zalcitabine—CYP3A4—Metapathway biotransformation—AKR1B10—uterine cancer	4.67e-05	0.00281	CbGpPWpGaD
Zalcitabine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	4.5e-05	0.00271	CbGpPWpGaD
Zalcitabine—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	4.44e-05	0.00267	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—POLD1—uterine cancer	4.43e-05	0.00267	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—POLD1—uterine cancer	4.37e-05	0.00263	CbGpPWpGaD
Zalcitabine—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	4.34e-05	0.00261	CbGpPWpGaD
Zalcitabine—CYP2D6—Metapathway biotransformation—GPX3—uterine cancer	4.28e-05	0.00258	CbGpPWpGaD
Zalcitabine—CYP2C9—Metapathway biotransformation—GPX3—uterine cancer	4.24e-05	0.00255	CbGpPWpGaD
Zalcitabine—CYP3A5—Biological oxidations—CYP19A1—uterine cancer	4.17e-05	0.00251	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—AKR1C1—uterine cancer	4.15e-05	0.00249	CbGpPWpGaD
Zalcitabine—CYP3A5—Metapathway biotransformation—CYP19A1—uterine cancer	4.11e-05	0.00247	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—AKR1C1—uterine cancer	4.08e-05	0.00246	CbGpPWpGaD
Zalcitabine—CYP2D6—Biological oxidations—CYP11A1—uterine cancer	4.03e-05	0.00242	CbGpPWpGaD
Zalcitabine—CYP2C9—Biological oxidations—CYP11A1—uterine cancer	4e-05	0.0024	CbGpPWpGaD
Zalcitabine—CYP2D6—Metapathway biotransformation—CYP11A1—uterine cancer	3.98e-05	0.00239	CbGpPWpGaD
Zalcitabine—CYP2C9—Metapathway biotransformation—CYP11A1—uterine cancer	3.94e-05	0.00237	CbGpPWpGaD
Zalcitabine—CYP2D6—Metapathway biotransformation—AKR1C3—uterine cancer	3.75e-05	0.00226	CbGpPWpGaD
Zalcitabine—CYP2C9—Metapathway biotransformation—AKR1C3—uterine cancer	3.72e-05	0.00224	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—RRM2—uterine cancer	3.7e-05	0.00222	CbGpPWpGaD
Zalcitabine—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	3.65e-05	0.0022	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—RRM2—uterine cancer	3.64e-05	0.00219	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—DCN—uterine cancer	3.59e-05	0.00216	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	3.55e-05	0.00213	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—DCN—uterine cancer	3.53e-05	0.00213	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—CYP11A1—uterine cancer	3.38e-05	0.00203	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—CYP11A1—uterine cancer	3.33e-05	0.002	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—AKR1C3—uterine cancer	3.19e-05	0.00192	CbGpPWpGaD
Zalcitabine—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	3.19e-05	0.00192	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—AKR1C3—uterine cancer	3.14e-05	0.00189	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—SRD5A2—uterine cancer	3.1e-05	0.00186	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—NDUFB11—uterine cancer	3.1e-05	0.00186	CbGpPWpGaD
Zalcitabine—CYP2D6—Biological oxidations—CYP19A1—uterine cancer	2.97e-05	0.00178	CbGpPWpGaD
Zalcitabine—CYP2C9—Biological oxidations—CYP19A1—uterine cancer	2.94e-05	0.00177	CbGpPWpGaD
Zalcitabine—CYP2D6—Metapathway biotransformation—CYP19A1—uterine cancer	2.92e-05	0.00176	CbGpPWpGaD
Zalcitabine—CYP2C9—Metapathway biotransformation—CYP19A1—uterine cancer	2.9e-05	0.00174	CbGpPWpGaD
Zalcitabine—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	2.8e-05	0.00168	CbGpPWpGaD
Zalcitabine—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	2.64e-05	0.00159	CbGpPWpGaD
Zalcitabine—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	2.6e-05	0.00156	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	2.56e-05	0.00154	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—STAR—uterine cancer	2.56e-05	0.00154	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—STK11—uterine cancer	2.49e-05	0.0015	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—CYP19A1—uterine cancer	2.49e-05	0.0015	CbGpPWpGaD
Zalcitabine—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	2.45e-05	0.00148	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—STK11—uterine cancer	2.45e-05	0.00147	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—CYP19A1—uterine cancer	2.45e-05	0.00147	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—STAR—uterine cancer	2.24e-05	0.00135	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—AKR1B1—uterine cancer	2.24e-05	0.00135	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—SRD5A2—uterine cancer	2.24e-05	0.00135	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—NDUFB11—uterine cancer	2.24e-05	0.00135	CbGpPWpGaD
Zalcitabine—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	1.94e-05	0.00117	CbGpPWpGaD
Zalcitabine—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	1.91e-05	0.00115	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	1.88e-05	0.00113	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—MTHFR—uterine cancer	1.87e-05	0.00112	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—MTHFR—uterine cancer	1.84e-05	0.00111	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—POLD1—uterine cancer	1.76e-05	0.00106	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—AKR1C1—uterine cancer	1.65e-05	0.00099	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—AKR1B1—uterine cancer	1.62e-05	0.000975	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—STAR—uterine cancer	1.62e-05	0.000975	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—NDUFB11—uterine cancer	1.59e-05	0.000959	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—SRD5A2—uterine cancer	1.59e-05	0.000959	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—NDUFB11—uterine cancer	1.58e-05	0.00095	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—SRD5A2—uterine cancer	1.58e-05	0.00095	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.53e-05	0.000923	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—RRM2—uterine cancer	1.47e-05	0.000882	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.45e-05	0.000872	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—DCN—uterine cancer	1.42e-05	0.000856	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—CYP11A1—uterine cancer	1.34e-05	0.000807	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—POLD1—uterine cancer	1.27e-05	0.000765	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—AKR1C3—uterine cancer	1.27e-05	0.000762	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—AKR1C1—uterine cancer	1.19e-05	0.000715	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—AKR1B1—uterine cancer	1.15e-05	0.000693	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—STAR—uterine cancer	1.15e-05	0.000693	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—STAR—uterine cancer	1.14e-05	0.000687	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—AKR1B1—uterine cancer	1.14e-05	0.000687	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.13e-05	0.000679	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—RRM2—uterine cancer	1.06e-05	0.000638	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—SRD5A2—uterine cancer	1.04e-05	0.000627	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—NDUFB11—uterine cancer	1.04e-05	0.000627	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—PTEN—uterine cancer	1.04e-05	0.000625	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—DCN—uterine cancer	1.03e-05	0.000619	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—PTEN—uterine cancer	1.02e-05	0.000616	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—EP300—uterine cancer	9.92e-06	0.000597	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—STK11—uterine cancer	9.87e-06	0.000594	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—CYP19A1—uterine cancer	9.87e-06	0.000594	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—EP300—uterine cancer	9.77e-06	0.000587	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—CYP11A1—uterine cancer	9.69e-06	0.000583	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—AKR1C3—uterine cancer	9.15e-06	0.000551	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—POLD1—uterine cancer	9.04e-06	0.000544	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—POLD1—uterine cancer	8.96e-06	0.000539	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—AKR1C1—uterine cancer	8.46e-06	0.000509	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—AKR1C1—uterine cancer	8.38e-06	0.000504	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—RRM2—uterine cancer	7.54e-06	0.000453	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—AKR1B1—uterine cancer	7.53e-06	0.000453	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—STAR—uterine cancer	7.53e-06	0.000453	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—RRM2—uterine cancer	7.47e-06	0.000449	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—MTHFR—uterine cancer	7.41e-06	0.000446	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—PIK3CA—uterine cancer	7.34e-06	0.000441	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—DCN—uterine cancer	7.32e-06	0.00044	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—DCN—uterine cancer	7.25e-06	0.000436	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—PIK3CA—uterine cancer	7.22e-06	0.000435	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—STK11—uterine cancer	7.13e-06	0.000429	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—CYP19A1—uterine cancer	7.13e-06	0.000429	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—CYP11A1—uterine cancer	6.89e-06	0.000415	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—CYP11A1—uterine cancer	6.83e-06	0.000411	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—AKR1C3—uterine cancer	6.51e-06	0.000392	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—AKR1C3—uterine cancer	6.45e-06	0.000388	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—AKT1—uterine cancer	5.99e-06	0.00036	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—POLD1—uterine cancer	5.91e-06	0.000356	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—AKT1—uterine cancer	5.9e-06	0.000355	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—AKR1C1—uterine cancer	5.53e-06	0.000333	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—MTHFR—uterine cancer	5.36e-06	0.000322	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—STK11—uterine cancer	5.07e-06	0.000305	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—CYP19A1—uterine cancer	5.07e-06	0.000305	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—STK11—uterine cancer	5.03e-06	0.000302	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—CYP19A1—uterine cancer	5.03e-06	0.000302	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—RRM2—uterine cancer	4.93e-06	0.000296	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—DCN—uterine cancer	4.78e-06	0.000288	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	4.72e-06	0.000284	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—CYP11A1—uterine cancer	4.51e-06	0.000271	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.5e-06	0.000271	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—AKR1C3—uterine cancer	4.26e-06	0.000256	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—PTEN—uterine cancer	4.12e-06	0.000248	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—EP300—uterine cancer	3.93e-06	0.000237	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—MTHFR—uterine cancer	3.81e-06	0.000229	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—MTHFR—uterine cancer	3.78e-06	0.000227	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.33e-06	0.0002	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—STK11—uterine cancer	3.32e-06	0.000199	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—CYP19A1—uterine cancer	3.32e-06	0.000199	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—PTEN—uterine cancer	2.98e-06	0.000179	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—PIK3CA—uterine cancer	2.91e-06	0.000175	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—EP300—uterine cancer	2.84e-06	0.000171	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—MTHFR—uterine cancer	2.49e-06	0.00015	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—AKT1—uterine cancer	2.38e-06	0.000143	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—PTEN—uterine cancer	2.12e-06	0.000128	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—PIK3CA—uterine cancer	2.1e-06	0.000127	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—PTEN—uterine cancer	2.1e-06	0.000126	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—EP300—uterine cancer	2.02e-06	0.000122	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—EP300—uterine cancer	2e-06	0.000121	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—AKT1—uterine cancer	1.72e-06	0.000103	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—PIK3CA—uterine cancer	1.5e-06	9e-05	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—PIK3CA—uterine cancer	1.48e-06	8.92e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—PTEN—uterine cancer	1.39e-06	8.34e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—EP300—uterine cancer	1.32e-06	7.95e-05	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—AKT1—uterine cancer	1.22e-06	7.35e-05	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—AKT1—uterine cancer	1.21e-06	7.29e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—PIK3CA—uterine cancer	9.78e-07	5.88e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—AKT1—uterine cancer	7.99e-07	4.81e-05	CbGpPWpGaD
